Biotechnology

Yiling's Lianhua Health Products Well-received: CICPE

SHIJIAZHUANG, China, Aug. 5, 2022 /PRNewswire/ -- As China's first national-level consumer expo and the largest such kind in theAsia-pacific region, the 2nd China International Consumer Products Expo (CICPE) attracted many audiences from different countries. And as the TOP 10 Chinese TCM Enterpr...

2022-08-05 15:54 3758

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

* Collaboration to accelerate the development and access of oncology medicines for cancer patients inChina * Clinical trial programs combining two of Sanofi's prioritized oncology assets with sintilimab, the leading checkpoint inhibitor inChina, to address some of the most prevalent solid tum...

2022-08-04 23:30 3728

MGI Announces Commercial Availability of HotMPS Sequencing Chemistry*and Instrument**in the United Kingdom

SHENZHEN, China, July 28, 2022 /PRNewswire/ -- MGI Tech (MGI) announced that its innovative HotMPS sequencing chemistry* and instrument** are commercially available in theUnited Kingdom, from 23rd June 2022. Further details will be communicated during the 17th Annual Meeting of the International ...

2022-08-04 22:50 2397

Genesis Capital invests in Crux Biolabs, a leading bioanalytical laboratory to the clinical trials sector

* Crux Biolabs is a decade-old Australian leader in bioanalytics, customised biomarker detection, cell assay development, clinical and pre-clinical testing with particular strength in the immuno-oncology clinical trials market * Genesis Capital is partnering with existing management to expand ...

2022-08-04 22:01 3058

CGBio Signing a North America Out-license Contract on "Novosis rhBMP-2," a Bone Substitute with Orthofix, USA

* Embarking on a successful journey of exporting its home-grown product technology toNorth America, the largest market for bone substitutes * Enabling fast bone formation by applying bone morphogenetic protein (rhBMP-2) and next-generation synthetic carrier SEOUL, South Korea and LEWISVILLE, ...

2022-08-04 21:00 2135

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

* Radiopharm will shortly initiate a PD-L1 Phase 1 therapeutic study in Australia in patients with NSCLC * Radiopharm acquired from NanoMab, Ltd. worldwide rights to PD-L1 technology for therapeutic use, as well as to imaging rights inChina MELBOURNE, Australia, Aug. 3, 2022 /PRNewswire/ -- R...

2022-08-04 10:15 1371

Firmenich Appoints Maurizio Clementi ad interim President of its Taste & Beyond Division

GENEVA, Aug. 3, 2022 /PRNewswire/ -- Firmenich, the world's largest privately-owned fragrance and taste company, is pleased to announce the appointment ofMaurizio Clementi as ad interim President of its Taste & Beyond division, effective immediately. This move follows former PresidentEmmanuel Bu...

2022-08-03 20:57 1996

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

-   STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. -   STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd. (237690:KOSDAQ) annou...

2022-08-03 20:00 1700

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, Aug. 3, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company completed the enrollment of 121 patients for its pha...

2022-08-03 19:38 1306

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active metabolite ASC10-A, which is the same active metabolite of molnupiravir -- Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a n...

2022-08-03 16:50 2075

Yidu Tech Releases FY2022 ESG Report, Using Socially Beneficial Technology to Drive the Sustainable Development of "Green Healthcare"

HONG KONG, Aug. 3, 2022 /PRNewswire/ -- The digital economy powered by innovative technologies such as artificial intelligence ("AI") and big data has become one of the most powerful drivers of economic growth since the COVID-19 outbreak, in keeping withChina's core strategy of "digitalization, ...

2022-08-03 15:09 1794

Ogawa World Berhad Won the Asia Pacific Enterprise Awards 2022 Malaysia under Inspirational Brand Category

KUALA LUMPUR, Malaysia, Aug. 3, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the 13th Asia Pacific Enterprise Awards (APEA) 2022 Malaysia, is pleased to recognize 47 exceptional business leaders and enterprises that have played a vital role in shapingMalaysia's entrepreneurial landscape...

2022-08-03 13:14 2817

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molecule with global rights. *  ATG-101 demonstrates potent in vivo efficacy in anti-PD-1/PD-L1 resistant mouse tumor models. SHANGHAI and HONG KONG, Aug. 3, 2022 /PRNewswire/ -- Antengene Corpora...

2022-08-03 08:30 1834

Sanyou Biopharmaceuticals Closed the Series B+ Financing Round of Tens of Millions of RMB Led by Huatai Zijin

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. announced that it has closed the Series B+ financing round of tens of millions of RMB. In this round of financing led by Zijin Hongyun Fund and Huatai Guoxin Fund under Huatai Zijin, Sanyou also received follow-on investme...

2022-08-03 08:00 1590

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA and FLORENCE, Italy, Aug. 2, 2022 /PRNewswire/ -- Context Therapeutics Inc. ("Context" or the "Company") (...

2022-08-02 22:49 2454

GenKOre develops hypercompact base editing system

DAEJEON, South Korea , Aug. 2, 2022 /PRNewswire/ -- GenKOre (homepage: www.genkore.com ), a biotech start-up in Korea, had a study on the development of hypercompact adenine base editors (ABEs) published on Nature Chemical Biology onAugust 2, 2022.

2022-08-02 22:44 1904

Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Aug. 2, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today a...

2022-08-02 21:00 1781

Metabolon Awarded ISO 9001:2015 Recertification

ISO 9001:2015 certificate re-issued to Metabolon following continued demonstrated ability to meet customer, statutory, and regulatory standards MORRISVILLE, N.C., Aug. 2, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance drug development and ...

2022-08-02 20:57 1567

CARsgen Appoints Dr. Hua Jiang as Executive Director

SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatDr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Direct...

2022-08-02 20:50 1916

Sironax Announces Closing of $200 Million Series B Financing

Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases BEIJING, Aug. 2, 2022 /PRNewswire/ -- Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with...

2022-08-02 19:00 1920
1 ... 113114115116117118119 ... 275

Week's Top Stories